Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/176163
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Moreno Grau, Sonia | - |
dc.contributor.author | Rodríguez Gómez, Octavio | - |
dc.contributor.author | Sanabria, Ángela | - |
dc.contributor.author | Pérez Cordón, Alba | - |
dc.contributor.author | Sánchez Ruiz, Domingo | - |
dc.contributor.author | Abdelnour, Carla | - |
dc.contributor.author | Valero, Sergi | - |
dc.contributor.author | Hernández, Isabel | - |
dc.contributor.author | Rosende-Roca, Maitée | - |
dc.contributor.author | Mauleón, Ana | - |
dc.contributor.author | Vargas, Liliana | - |
dc.contributor.author | Lafuente, Asunción | - |
dc.contributor.author | Gil, Silvia | - |
dc.contributor.author | Santos Santos, Miguel A. | - |
dc.contributor.author | Alegret, Montserrat | - |
dc.contributor.author | Espinosa, Ana | - |
dc.contributor.author | Ortega, Gemma | - |
dc.contributor.author | Guitart, Marina | - |
dc.contributor.author | Gailhajanet, Anna | - |
dc.contributor.author | Rojas, Itziar de | - |
dc.contributor.author | Sotolongo Grau, Óscar | - |
dc.contributor.author | Ruiz, Susana | - |
dc.contributor.author | Aguilera, Nuria | - |
dc.contributor.author | Papasey, Judith | - |
dc.contributor.author | Martín, Elvira | - |
dc.contributor.author | Peleja, Esther | - |
dc.contributor.author | Lomeña Caballero, Francisco Juan | - |
dc.contributor.author | Campos, Francisco | - |
dc.contributor.author | Vivas, Assumpta | - |
dc.contributor.author | Gómez Chiari, Marta | - |
dc.contributor.author | Tejero, Miguel Ángel | - |
dc.contributor.author | Giménez, Joan | - |
dc.contributor.author | Serrano Ríos, Manuel | - |
dc.contributor.author | Orellana, Adelina | - |
dc.contributor.author | Tárraga, Lluís | - |
dc.contributor.author | Ruiz, Agustín | - |
dc.contributor.author | Boada, Mercè | - |
dc.contributor.author | Alzheimer's Disease Neuroimaging Initiative | - |
dc.contributor.author | FACEHBI study group | - |
dc.date.accessioned | 2021-04-12T09:05:07Z | - |
dc.date.available | 2021-04-12T09:05:07Z | - |
dc.date.issued | 2017-11-20 | - |
dc.identifier.uri | http://hdl.handle.net/2445/176163 | - |
dc.description.abstract | Introduction: Subjective cognitive decline (SCD) has been proposed as a potential preclinical stage of Alzheimer's disease (AD). Nevertheless, the genetic and biomarker profiles of SCD individuals remain mostly unexplored. Methods: We evaluated apolipoprotein E (APOE) ε4's effect in the risk of presenting SCD, using the Fundacio ACE Healthy Brain Initiative (FACEHBI) SCD cohort and Spanish controls, and performed a meta-analysis addressing the same question. We assessed the relationship between APOE dosage and brain amyloid burden in the FACEHBI SCD and Alzheimer's Disease Neuroimaging Initiative cohorts. Results: Analysis of the FACEHBI cohort and the meta-analysis demonstrated SCD individuals presented higher allelic frequencies of APOE ε4 with respect to controls. APOE dosage explained 9% (FACEHBI cohort) and 11% (FACEHBI and Alzheimer's Disease Neuroimaging Initiative cohorts) of the variance of cerebral amyloid levels. Discussion: The FACEHBI sample presents APOE ε4 enrichment, suggesting that a pool of AD patients is nested in our sample. Cerebral amyloid levels are partially explained by the APOE allele dosage, suggesting that other genetic or epigenetic factors are involved in this AD endophenotype. | - |
dc.format.extent | 10 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Wiley | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.jalz.2017.10.005 | - |
dc.relation.ispartof | Alzheimer's & Dementia, 2017, vol. 14, p. 634-643 | - |
dc.relation.uri | https://doi.org/10.1016/j.jalz.2017.10.005 | - |
dc.rights | cc by-nc-nd (c) Moreno Grau, 2017 | - |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Malaltia d'Alzheimer | - |
dc.subject.classification | Malalties del sistema nerviós | - |
dc.subject.other | Alzheimer's disease | - |
dc.subject.other | Nervous system Diseases | - |
dc.title | Exploring APOE genotype effects on Alzheimer's disease risk and amyloid β burden in individuals with subjective cognitive decline: The FundacioACE Healthy Brain Initiative (FACEHBI) study baseline results | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-04-09T11:04:34Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 29156223 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
j.jalz.2017.10.005.pdf | 419.19 kB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License